

Correction

There was an error in Table 1 of the article “A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated with Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion” by Hashim et al, which was published in the JDD August 2017 issue.¹

The corrected table is below.

Table 1. Summary Statistics for Epidermal and Dermal Thickness
Values are mean (SD); median [min, max].

Treatment	Time	Epidermal Thickness	Dermal Thickness
Betamethasone	Baseline	0.56 (0.19); 0.51 [0.29, 1.04]	3.5 (0.7); 3.5 [2.6, 5.6]
	Week 4	0.33 (0.17); 0.26 [0.14, 0.81]	3.2 (0.5); 3.3 [2.4, 4.3]
	Average Change	-0.23 (0.18); -0.17 [-0.54, 0.04]	-0.27 (0.65); -0.30 [-1.63, 0.68]
	Percent Change	-39% (24); -35% [-74%, 9%]	-5.6% (16.9); -9% [-32%, 24%]
Taclonex	Baseline	0.49 (0.14); 0.45 [0.26, 0.84]	3.5 (0.5); 3.6 [2.7, 4.4]
	Week 4	0.46 (0.25); 0.40 [0.12, 0.94]	3.4 (0.5); 3.4 [2.6, 4.5]
	Average Change	-0.04 (0.2); -0.08 [-0.26, 0.40]	-0.10 (0.35); -0.19 [-0.45, 0.80]
	Percent Change	-8% (48%); -19% [-64%, 109%]	-2% (12); -5% [-11%, 29%]

References

1. PW. Hashim, J.K. Nia, D. Terrano, et al. A comparative study to evaluate epidermal barrier integrity of psoriasis patients treated with calcipotriene/betamethasone topical suspension versus betamethasone dipropionate 0.05% lotion. *J Drugs Dermatol*. 2017;16(8):747-752.